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ABSTRACT There is growing interest in utilizing antibody-dependent cellular cyto-
toxicity (ADCC) to eliminate infected cells following reactivation from HIV-1 latency.
A potential barrier is that HIV-1-speciﬁc ADCC antibodies decline in patients on
long-term antiretroviral therapy (ART) and may not be sufﬁcient to eliminate reacti-
vated latently infected cells. It is not known whether reactivation from latency with
latency-reversing agents (LRAs) could provide sufﬁcient antigenic stimulus to boost
HIV-1-speciﬁc ADCC. We found that treatment with the LRA panobinostat or a short
analytical treatment interruption (ATI), 21 to 59 days, was not sufﬁcient to stimulate
an increase in ADCC-competent antibodies, despite viral rebound in all subjects who
underwent the short ATI. In contrast, a longer ATI, 2 to 12 months, among subjects
enrolled in the Strategies for Management of Antiretroviral Therapy (SMART) trial
robustly boosted HIV-1 gp120-speciﬁc Fc receptor-binding antibodies and ADCC
against HIV-1-infected cells in vitro. These results show that there is a lag between
viral recrudescence and the boosting of ADCC antibodies, which has implications for
strategies toward eliminating latently infected cells.
IMPORTANCE The “shock and kill” HIV-1 cure strategy aims to reactivate HIV-1 ex-
pression in latently infected cells and subsequently eliminate the reactivated cells
through immune-mediated killing. Several latency reversing agents (LRAs) have been
examined in vivo, but LRAs alone have not been able to achieve HIV-1 remission and
prevent viral rebound following analytical treatment interruption (ATI). In this study,
we examined whether LRA treatment or ATI can provide sufﬁcient antigenic stimulus
to boost HIV-1-speciﬁc functional antibodies that can eliminate HIV-1-infected cells.
Our study has implications for the antigenic stimulus required for antilatency strate-
gies and/or therapeutic vaccines to boost functional antibodies and assist in elimi-
nating the latent reservoir.
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Amajor focus in the ﬁeld of human immunodeﬁciency virus type 1 (HIV-1) cureresearch is to develop agents and strategies that reactivate HIV-1 from latency,
induce killing of the reactivated cells, and achieve HIV-1 remission. Several latency-
reversing agents (LRAs) have been examined both in vitro and in vivo (1–7). An
emerging class of drugs that can potentially serve as LRAs is the histone deacetylase
inhibitors (HDACi), which act epigenetically to upregulate gene expression by promot-
ing the acetylation of DNA-bound histones (8). One HDACi that has shown promise in
reversing HIV-1 latency in vivo is panobinostat, which was administered to participants
three times per week, every second week, for 8 weeks (3). Panobinostat treatment
resulted in a signiﬁcant increase in cell-associated unspliced HIV-1 RNA and also
induced plasma viremia in a proportion of subjects. A decrease in total integrated HIV-1
DNA, however, was not detected, and panobinostat treatment failed to prevent re-
bound of viremia during analytical antiretroviral therapy (ART) interruption. Conse-
quently, reactivation of HIV-1 latency by panobinostat was not sufﬁcient to signiﬁcantly
reduce the viral reservoir, suggesting that complementing modalities need to be
harnessed to purge latently infected cells.
Elimination of reactivated cells expressing HIV-1 antigens on the surface could
theoretically be achieved through antibody-dependent cellular cytotoxicity (ADCC). If
viral protein expression is sufﬁciently induced, HIV-1-speciﬁc antibodies can target
reactivated cells by binding to the HIV-1 envelope protein (Env) expressed on the cell
surface (9). The fragment crystallizable (Fc) constant regions of these Env-bound
antibodies can then cross-link Fc gamma receptor IIIa (FcRIIIa) on innate effector cells,
such as natural killer (NK) cells or monocytes, and mediate cytolysis of the infected
target cells (10, 11).
A potential barrier for ADCC to eradicate the latent reservoir is that HIV-1-speciﬁc
ADCC antibodies decline in subjects on long-term ART (12, 13). It is not known whether
host ADCC antibodies will need to be boosted prior to latency reversal for ADCC to be
effective in eliminating reactivated cells. If sufﬁcient reactivation of the latent reservoir
can be achieved, the resulting increase in viremia could potentially provide antigenic
stimulation to boost ADCC antibody levels. The recrudescence of virus after an analyt-
ical treatment interruption (ATI) could provide a larger antigenic stimulus to trigger
memory B cell responses and boost ADCC antibody levels as well.
To assess the boosting of HIV-1-speciﬁc ADCC antibodies after viral recrudescence,
we analyzed plasma samples from the panobinostat clinical trial that were obtained
pre- and post-panobinostat treatment and after a subsequent brief ART interruption
(median, 21 days) (3). To analyze whether a larger antigenic stimulus from a longer
period of ART interruption (2 to 12 months) could lead to a bigger boost in ADCC
antibodies, we analyzed plasma samples from the SMART (Strategies for Management
of Antiretroviral Therapy) trial, which compared the effects of continuous and episodic
use of ART guided by CD4 T cell counts (14). Our results show that neither panobi-
nostat treatment nor a very short ATI boosted HIV-1-speciﬁc ADCC, and ART interrup-
tion of 2 months or more was required to boost HIV-1-speciﬁc ADCC.
RESULTS
Panobinostat treatment in ART-suppressed subjects does not boost HIV-1-
speciﬁc antibody responses. We ﬁrst studied 14 ART-suppressed HIV-1-infected sub-
jects who received 20 mg of panobinostat orally three times per week, every second
week, for a period of 8 weeks (3). Panobinostat disrupted HIV-1 latency in vivo, with an
increase in cell-associated HIV-1 RNA and an increase in the proportion of plasma
samples during panobinostat treatment testing positive for HIV-1 RNA (3). We hypoth-
esized that this modest amount of reactivation could trigger memory B cell responses
to boost HIV-1-speciﬁc antibodies. However, we found no difference in the concentra-
tion of gp120-speciﬁc IgG in the plasma samples pre- and post-panobinostat treatment
(14.7 g/ml [6.6 to 51.9] versus 16.5 g/ml [5.9 to 49.3]; not signiﬁcant [ns] [Fig. 1A];
median [interquartile range]).
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HIV-1-speciﬁc antibodies could theoretically eliminate reactivated latently infected
cells through Fc-mediated effector functions, including ADCC. As a surrogate measure
of Fc effector function, we performed a novel enzyme-linked immunosorbent assay
(ELISA) to examine the ability of gp120-speciﬁc antibodies within the plasma samples
to cross-link dimeric FcRIIIa, the primary Fc receptor responsible for ADCC (Fig. 1B). We
show that panobinostat was not able to boost the level of gp120-speciﬁc antibodies
capable of cross-linking dimeric FcRIIIa (normalized optical density at 450 nm [OD450],
0.430 [0.086 to 0.755] versus 0.421 [0.093 to 0.753]; ns [Fig. 1C]).
To validate our results with a functional ADCC assay, we performed an infected-cell
elimination assay and assessed whether panobinostat treatment boosted HIV-1-speciﬁc
ADCC. This assay examines the loss of HIV-1 p24 cells; the gating strategy to analyze
elimination of an HIV-1-infected cell line is shown in Fig. 2A. We found that panobi-
nostat treatment did not increase HIV-1-speciﬁc ADCC (pre-panobinostat area under
the curve [AUC], 16.9 [12.2 to 21.8], versus post-panobinostat AUC, 18.2 [14.3 to 23.5];
ns [Fig. 2B]). We found that the FcRIIIa dimer-binding ELISA correlated signiﬁcantly
with the functional ADCC assay (P  0.0004; r  0.58).
A short ATI post-panobinostat treatment was also insufﬁcient to boost HIV-1-
speciﬁc antibody responses. As part of the panobinostat trial, 9 subjects underwent
a short ATI to examine whether panobinostat could delay viral rebound in the absence
of ART. All 9 subjects had rebound in HIV-1 viremia, and the median time for plasma
viral load to exceed 50 copies/ml was 14 days (range, 10 to 45) (Table 1). We
hypothesized that viral rebound from the short ATI following panobinostat treatment
could provide a larger stimulus to boost HIV-1-speciﬁc antibodies. We examined plasma
samples obtained immediately prior to ART restart from all 9 subjects during the ATI.
The median length of ATI for the 9 subjects was 21 days (range, 21 to 59), while the
median length of viremia during ATI (days from emergence of virus in plasma to ART
restart) was 14 days (range, 7 to 18). The subjects had a median viral load of 2.5  104
copies/ml (range, 2.5  103 to 1.6  106) immediately before restarting ART (Table 1).
We measured the concentration of gp120-speciﬁc IgG antibodies and found no signif-
icant difference between the post-panobinostat treatment and ATI time points (20.6
g/ml [7.6 to 50.8] versus 14.4 g/ml [9.3 to 37.2]; ns [Fig. 3A]). Similarly, as a surrogate
FIG 1 HIV-1-speciﬁc antibody responses following panobinostat treatment. (A) Concentrations of gp120-
speciﬁc IgG antibodies pre- and post-panobinostat treatment. (B) ELISA to measure dimeric FcRIIIa
binding. Ninety-six-well ELISA plates were ﬁrst coated with 50 ng/well of HIV-1BaL gp120 prior to addition
of diluted HIV-1 plasma samples (containing HIV-1-speciﬁc IgG antibodies). Biotinylated recombinant
dimeric FcRIIIa was then added, followed by HRP-conjugated streptavidin. The wells were developed
with TMB substrate, and absorbance was measured at 450 nm. (C) Levels of gp120-speciﬁc antibodies
that bind dimeric FcRIIIa pre- and post-panobinostat treatment. The cross-linking of recombinant
FcRIIIa was used as a surrogate measure of antibody Fc-mediated effector function. Statistical analyses
between matched pairs were performed using the Wilcoxon signed-rank test.
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of ADCC function, we found no difference in the level of gp120-speciﬁc antibodies
capable of binding dimeric FcRIIIa (normalized OD450, 0.622 [0.238 to 0.764] versus
0.522 [0.225 to 0.768]; ns [Fig. 3B]). To further study ADCC after this short ATI, we
performed the infected-cell elimination assay and found no difference in HIV-1-speciﬁc
ADCC in these 9 subjects (post-panobinostat AUC, 20.6 [15.7 to 24.9], versus ATI AUC,
17.1 [15.0 to 22.9]; ns [Fig. 3C]).
HIV-1-speciﬁc antibody responses and ADCC increase signiﬁcantly following 2
months of ATI. The data presented thus far demonstrate that neither panobinostat nor
a short ATI post-panobinostat treatment was able to boost HIV-1-speciﬁc ADCC re-
sponses. Since the short ATI, a median of 21 days (range, 21 to 59 days), was not
sufﬁcient, we next assessed whether a longer ATI, 2 to 12 months, could stimulate
HIV-1-speciﬁc ADCC. We obtained 60 samples from the SMART trial, with 30 subjects
randomly assigned to the continuous use of ART and 30 assigned to undergo ART
interruption (Table 2). The subjects in the ART group served as negative controls for the
ATI samples, as we have previously shown that continuous ART results in a slow decline
FIG 2 HIV-1-speciﬁc ADCC following panobinostat treatment. The infected-cell elimination assay was performed to
assess ADCC against the HIV-1-infected 8E5/LAV cell line. Healthy donor PBMCs were used as effector cells and
incubated with the target cells at an effector/target ratio of 1:1, with plasma samples added at 10-fold serial
dilutions from 1:100 to 1:100,000. (A) Plots depict the gating strategy used to analyze ﬂow cytometry data for the
infected-cell elimination assay. Shown here is a representative sample with both effector and target cells. The ﬁrst
gate was set using a target cell-only control (based on forward and side scatter parameters) and applied to all
samples. Next, gating was on single cells, live cells, eFluor 670 eFluor 450 target cells, and lastly, HIV-1-infected
cells (determined by staining for HIV-1 p24). The bottom images are two representative plots showing elimination
of p24 cells in the presence of HIV-1 plasma compared to HIV-1- plasma. Percent ADCC was calculated and is
plotted against log10(dilution1) to determine the area under curve (AUC) for each subject at each time point. (B)
Anti-HIV-1 ADCC for 14 subjects pre- and post-panobinostat treatment. Matched pairs were analyzed using the
Wilcoxon signed-rank test. The ADCC data were averaged from 3 independent experiments.
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in ADCC responses (12, 13). Eight subjects in the ART group were excluded from our
analyses because they either failed or stopped ART and had viral loads exceeding 500
copies/ml at one or more time points. The viral loads of subjects in the two groups are
shown in Fig. 4A. Subjects in the ART group had viral loads suppressed below 500
copies/ml for all 12 months, whereas almost all subjects in the ATI group had viral
rebound throughout the 12 months.
We examined whether this longer ATI of 2 to 12 months could boost the level of
gp120-speciﬁc IgG. For subjects in the ATI group, the concentration of gp120-speciﬁc
IgG signiﬁcantly increased 2, 4, and 12 months post-ATI (Fig. 4B). For subjects in the ART
group, there was a gradual decrease in gp120-speciﬁc IgG after 4 to 12 months of
continuous ART (Fig. 4B). This decline in gp120-speciﬁc antibodies is likely due to the
lack of antigenic stimulation resulting from ART-mediated viral suppression. Next, as a
surrogate measure of antibody Fc-mediated effector function, we measured the level of
gp120-speciﬁc antibodies capable of cross-linking dimeric FcRIIIa. We detected a
signiﬁcant increase in these FcRIIIa dimer-binding antibodies after 2, 4, and 12 months
of ATI and a signiﬁcant decrease after 12 months of continuous ART (Fig. 4C). There was
no signiﬁcant difference in the baseline levels of FcRIIIa dimer-binding antibodies
between the ART group and the ATI group (normalized OD450, 0.490 [0.181 to 0.751] for
the ART group versus 0.331 [0.111 to 0.587] for the ATI group; ns).
To validate these results with a functional ADCC assay, we performed the infected-
cell elimination assay with a subset of the subjects. There was a trend toward an
increase in anti-HIV-1 ADCC for the ATI group at 4 months post-ATI and a signiﬁcant
increase 12 months post-ATI (baseline AUC, 29 [18.2 to 40.9], versus AUC at 4 months,
36.9 [31.1 to 46.4] [P 0.0507], and AUC at 12 months, 39.6 [34 to 44.1] [P 0.028] [Fig.
4D]). There were no signiﬁcant differences in anti-HIV-1 ADCC for the subjects who
remained on ART for 12 months. Similar to the case with panobinostat trial samples, we
found that the FcRIIIa dimer-binding ELISA correlated signiﬁcantly with the functional
ADCC assay for the SMART trial samples (P  0.0001; r  0.58).
The functional ADCC assay could detect a signiﬁcant increase in HIV-1-speciﬁc ADCC
only at 12 months post-ATI (P 0.028), whereas the FcRIIIa dimer-binding ELISA could
detect a much more signiﬁcant increase in ADCC antibodies earlier, at 4 months
post-ATI (P  0.0001). This suggests that the FcRIIIa dimer-binding ELISA is more
sensitive at detecting changes in ADCC antibodies and should be considered an
alternative assay to examine the level of antibodies capable of mediating effector
functions.
Modeling of the ATI-induced stimulus of ADCC antibodies. The lack of increase
in ADCC antibodies after panobinostat treatment and the subsequent short ATI may
have occurred for two reasons. Either (i) the viremia induced by panobinostat or
encountered during ATI was insufﬁcient to stimulate an increase in ADCC antibodies or
(ii) there was a signiﬁcant delay between viral recrudescence and the stimulation of
TABLE 1 Characteristics of panobinostat trial subjects who underwent ATIa
Subject
identiﬁer Age (yrs)
No. of days from ATI
to VL of >50
copies/ml
No. of days from VL of
>20 copies/ml to ART
restart
Length of
ATI (days)
VL before ART restart
(copies/ml)
CD4 before ART
restart (cells/mm3)
1 43 14 11 21 10,692 700
2 49 14 7 21 106,261 490
4 50 45 14 59 6,634 550
8 51 14 14 21 193,365 600
9 51 24 14 31 25,187 620
10 47 10 14 21 136,590 600
12 34 17 7 24 2,476 ND
17 49 10 18 28 1,573,968 1,180
18 28 14 7 21 8,595 1,180
Median (range) 49 (28–41) 14 (10–45) 14 (7–18) 21 (21–59) 25,187 (2,476–1,573,968) 610 (490–1,180)
aAll subjects were male. VL, viral load; ND, not determined.
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ADCC antibodies (which was not detected due to the early sampling time in the
panobinostat study). To analyze the relationship between the level of viremia and the
boosting of ADCC antibodies, we modeled the FcRIIIa dimer-binding antibody data
from the SMART trial. We ﬁrst calculated the rate of change in ADCC antibodies (FcRIIIa
dimer-binding antibodies) from baseline to 2 months and plotted the rates against the
viral loads at 2 months (Fig. 5). There was a signiﬁcant correlation between the rate of
increase in ADCC and viral loads at 2 months (r  0.67; P  0.0001). This suggests that
the level of viral antigenic stimulus is an important driver of the ADCC response
following ATI. We then performed orthogonal regression using the ATI samples to
determine the threshold viral load needed to induce an increase in ADCC antibodies.
The estimated threshold viral load (x-intercept of the regression line in Fig. 5) was rather
low, at approximately 326 RNA copies/ml. While this low threshold may be sufﬁcient to
initiate an increase in the level of ADCC antibodies, our data from the panobinostat trial
FIG 3 HIV-1-speciﬁc antibody responses and ADCC following a short ATI after panobinostat treatment.
Nine of the 15 subjects underwent ART interruption for a median of 21 days (range, 21 to 59 days), with
ART restarted following two consecutive viral load measurements of more than 1,000 copies/ml. The ATI
samples were obtained immediately prior to ART restart, and the duration of ATI for each subject is listed
in parentheses next to the subject IDs. (A) Concentrations of gp120-speciﬁc IgG antibodies for the 9
subjects pre- and post-panobinostat treatment and following a short ATI. (B) Levels of gp120-speciﬁc
antibodies that bind dimeric FcRIIIa pre- and post-panobinostat treatment and following a short ATI. (C)
Anti-HIV-1 ADCC for 9 subjects pre- and post-panobinostat treatment and following a short ATI.
Statistical analyses between multiple matched groups were performed using the Friedman test followed
by Dunn’s posttest. The ADCC data were averaged from 3 independent experiments.
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suggests that constant antigenic stimulus over longer periods will probably be required
to drive a meaningful increase in ADCC antibodies.
To assess the effect of time on the increase in ADCC antibodies after ATI, we plotted
the rate of change in ADCC antibodies against the difference in viral loads from
baseline to 2 months (Fig. 6A) and from 2 to 4 months (Fig. 6B). There was a signiﬁcant
correlation between the rate of ADCC and difference in viral loads from baseline to 2
months (r  0.64; P  0.0001) but not from 2 to 4 months (r  0.09; P  0.52). This
implies that the increase in ADCC antibodies from baseline to 2 months in the ATI
group was due to the substantial increase in viral load within the ﬁrst 2 months of ATI.
The lack of correlation between 2 and 4 months likely reﬂects most subjects reaching
a stable viral set point, with relatively small changes in viral loads from month 2
onwards and an equilibrium existing between constant antigenic exposure and the
ADCC antibody response.
DISCUSSION
There is growing interest in utilizing immune-mediated effector functions to elim-
inate infected cells following latency reversal (15, 16). ADCC antibodies are of particular
interest because they can potentially eliminate reactivated latently infected cells ex-
pressing HIV-1 Env (9). The LRA panobinostat induced an increase in cellular HIV-1 RNA
and plasma viremia (3); however, we found that this level of HIV-1 antigen expression
did not provide sufﬁcient antigenic stimulus to boost HIV-1-speciﬁc ADCC immunity.
Even a short ATI post-panobinostat treatment was unable to increase gp120-speciﬁc
FcRIIIa dimer-binding antibodies or ADCC against HIV-1-infected cells. However, for
the SMART trial subjects who interrupted ART, a signiﬁcant increase in ADCC antibodies
occurred within the ﬁrst 2 months of ATI. The level of recrudescent viremia correlated
strongly with the increase in ADCC antibodies after ATI in the SMART trial, suggesting
that a longer antigenic stimulus is a key driver of the ADCC response to an ATI.
Our study shows that LRA treatment alone was not sufﬁcient to boost preexisting
ADCC immunity against HIV-1, highlighting the need for immunological interventions
alongside latency reversal to eradicate the latent reservoir. A number of potential
therapeutic vaccines have improved anti-HIV-1 immune responses in vivo (17–20) or
delayed viral rebound during ATI in a macaque model (21) and could theoretically be
administered prior to latency reversal to prime the immune system for killing of
reactivated cells. A recent trial examined the combined effects of administering the
therapeutic vaccine Vacc-4x (22) and granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) along with the LRA romidepsin (23). While a decrease in total HIV-1 DNA
after immunization and romidepsin treatment could be detected, this combined “prime
and shock” strategy was unable to prevent viral rebound after the interruption of ART.
Further optimization of combinatorial approaches will likely be needed to measurably
affect the latent reservoir.
TABLE 2 Characteristics of SMART trial patients who either remained on ART or
underwent ATI for 12 months
Characteristic
Value for group
ART (n  22) ATI (n  30)
Sex, no. (%)
Male 17 (77) 22 (73)
Female 5 (23) 8 (27)
Age (yrs), median (range) 46.5 (36–58) 42.5 (31–58)
Baseline CD4 count (cells/mm3), median
(range)
683.5 (387–1,215) 837.5 (384–1,526)
Nadir CD4 count (cells/mm3), median (range) 200 (11–720) 281.5 (14–601)
Baseline viral load (copies/ml), median (range) 50 (50–400) 50 (50–400)
Prior recorded highest viral load (copies/ml),
median (range)
36,150 (320–545,136) 38,730.5 (50–742,932)
Duration from initiation of ART to study entry
(yrs), median (range)
7 (5–16) 6 (5–13)
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FIG 4 HIV-1-speciﬁc antibody responses and ADCC following 2 to 12 months of ATI. We obtained plasma samples
from subjects in the SMART trial who either continued receiving ART (ART; n  22) or interrupted ART (ATI; n  30) for
12 months. (A) HIV-1 viral loads. (B) Concentrations of gp120-speciﬁc IgG antibodies. (C) Levels of gp120-speciﬁc
antibodies that bind dimeric FcRIIIa. (D) Anti-HIV-1 ADCC responses in a subset of subjects who continued receiving
ART (n 8) or underwent ATI (n 10) for 12 months. The ADCC data were averaged from 2 independent experiments.
Red lines depict the medians of each group. Statistical analyses between baseline and the different time points were
performed using the Friedman test followed by Dunn’s posttest. *, P 0.05; **, P 0.01, ***, P 0.001; ****, P 0.0001.
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Despite viral rebound in all 9 panobinostat trial subjects who underwent a short ATI
(median of 21 days) post-panobinostat treatment, there was no increase in gp120-
speciﬁc IgG or ADCC antibodies. Eight of the 9 subjects had an ATI of only 21 to 31 days,
when their sample to measure ADCC was taken, and the actual duration of viremia was
even shorter, at 7 to 18 days. The one panobinostat-treated subject with an ATI of 59
days (subject 4) only had viral rebound for 14 days, was treated with ART during acute
infection, and had a very low baseline level of gp120-speciﬁc antibodies. In contrast, the
ﬁrst sample in the SMART trial was obtained at 2 months, by which time almost all
subjects had a rise in ADCC antibodies. This suggests that a substantial lag exists
between viral recrudescence and the stimulation of ADCC immunity after ATI. This is
consistent with the observation of delayed CD8 T cell responses after simian immu-
nodeﬁciency virus (SIV) challenge in macaques, where even after vaccination, virus-
speciﬁc CD8 T cells are thought to do “too little too late” to alter the course of early
infection (24). Anti-HIV-1 binding or ADCC antibodies might well have increased at a
later time point after the panobinostat trial ATI, but plasma samples were not available
for study. If future studies of HIV-1 control after LRA and/or immune modulation wish
to take advantage of virus-induced immunity after ATI, it will be necessary for ATIs to
be longer than that in the panobinostat trial. Our results are in line with a previous
study that examined the kinetics of anti-gp120 antibodies following ATI (25), in which
anti-gp120 antibody titers did not increase following 4 consecutive ATI cycles of 2
weeks off ART and 8 weeks on ART, despite a brief viral rebound every ATI cycle.
Anti-gp120 antibody titers increased only following a ﬁfth, longer ATI, 12 weeks.
Another study examined the effect of ATI on heterologous neutralizing antibody
responses in subjects who initiated ART during acute/early HIV-1 infection. The inves-
tigators found that neutralizing antibodies developed against some isolates only after
20 weeks of ATI (26).
From our modeling studies, we determined the level of viremia required to drive an
increase in ADCC antibodies to be 326 HIV RNA copies/ml. While this low threshold viral
load may seem promising for latency reversal studies, romidepsin, one of the most
potent LRAs tested in vivo, was able to induce only transient viral blips of 46 to 103
copies/ml in 5 out of 6 subjects in the ﬁrst clinical trial (4) and 21 to 619 copies/ml in
7 out of 16 subjects in a subsequent trial (23). This transient low-level viremia induced
by current LRAs will likely be insufﬁcient to stimulate an increase in ADCC antibodies.
In addition, our modeling does not take into account the lag between viral rebound
and the stimulation of ADCC immunity. Despite viral rebound exceeding 326 HIV RNA
copies/ml in all panobinostat-treated subjects who underwent ATI, we could not detect
FIG 5 Modeling of the ATI-induced stimulus of ADCC antibodies. The rate of change in ADCC antibodies
(dimeric FcRIIIa-binding antibodies) was calculated for the SMART trial subjects from baseline to 2
months and plotted against the viral loads at the 2-month time point. The red dots represent subjects
who were receiving ART, whereas the black dots represent subjects who interrupted ART. Orthogonal
regression was performed on the ATI samples (black line) to estimate the threshold viral load required
to induce an increase in ADCC antibodies. The correlation was performed with the nonparametric
Spearman correlation.
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a signiﬁcant increase in HIV-1-speciﬁc ADCC antibodies in the short period (21 to 59
days) these subjects were monitored.
An issue with stimulating preexisting ADCC responses to control reactivated latent
infection is that viral escape from ADCC antibodies might have occurred in the earlier
stages of infection (27), as has been described for cytotoxic T lymphocytes (28).
Furthermore, a high proportion of ADCC antibodies in HIV-1-infected sera recognize
CD4-induced epitopes on Env (29), which may be concealed on infected cells due to
HIV-1 Nef- and Vpu-mediated downregulation of CD4 (30). This could potentially be
overcome by using CD4 mimetic compounds that can expose CD4-induced epitopes on
Env, enhance binding of serum ADCC antibodies, and improve the killing of reactivated
cells (9, 31, 32). Additionally, the passive transfer of ADCC-mediating broadly neutral-
izing antibodies (bNAbs) after latency reversal might also be a feasible approach. While
ADCC has not been formally proven to be a mechanism of viral control in subjects
treated with bNAbs, many bNAbs have been shown to mediate ADCC in vitro (33–35)
and in vivo in HIV-1-infected humanized mouse models (36–38). The passive transfer of
single bNAbs in the setting of ATI in chronically infected individuals has also been
examined, with VRC01 and 3BNC117 delaying viral rebound by several weeks compared
to that in historical controls (39, 40). However, in most individuals, viral suppression was
not maintained and bNAb-resistant rebound viruses emerged as bNAb levels waned.
Careful consideration will need to be taken for bNAbs to be used as an antilatency
approach, as preexisting viruses that are resistant to some bNAbs may reside within the
latent reservoir (39, 41), and broad reactivation of genetically diverse HIV-1 proviruses can
be induced by LRAs in vivo (42). The complex task of prescreening individuals for bNAb-
resistant viruses and the combinatorial use of multiple bNAbs targeting different epitopes
on Env may be necessary for bNAbs to be effective as an antilatency approach (36).
In summary, we show that panobinostat treatment or a short ATI following pano-
binostat treatment did not stimulate ADCC. However, a longer ATI, 2 to 12 months,
robustly boosted ADCC antibodies and ADCC against HIV-1-infected cells, suggesting
that there may be a lag between viral recrudescence and the stimulation of ADCC
immunity after ATI. These data have implications for the antigenic stimulus required for
antilatency strategies or therapeutic vaccines to boost ADCC in the hope of eradicating
the latent reservoir.
MATERIALS AND METHODS
Clinical samples. The panobinostat trial enrolled 15 HIV-1-infected subjects on ART, 14 of whom had
samples available and were included in this study. The subjects received 20 mg of panobinostat orally
three times per week, every second week, for a period of 8 weeks (3). Nine of the 15 subjects underwent
ART interruption after completion of panobinostat treatment for a median of 21 days (range, 21 to 59
days), with ART restarted following two consecutive viral load measurements of more than 1,000
copies/ml. We analyzed plasma samples collected 4 weeks before the ﬁrst dose of panobinostat and 5
FIG 6 Correlations between the rate of change in ADCC versus the difference in viral load from baseline to 2
months (A) and 2 to 4 months (B). The red dots represent subjects who were receiving ART, whereas the black dots
represent subjects who interrupted ART. Correlations were performed with the nonparametric Spearman
correlation.
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weeks after completion of panobinostat dosing. For the 9 subjects who underwent ART interruption, we
analyzed samples obtained immediately prior to ART restart following interruption.
In the SMART trial, HIV-1-infected subjects with CD4 cell counts above 350 cells/mm3 were randomly
assigned to the continuous use of ART or the episodic use of ART (ATI) (14). For subjects who underwent
ART interruption, ART was restarted when CD4 cell counts decreased to less than 250 cells/mm3. For the
purposes of our study, we obtained plasma samples from 30 subjects in the ATI group who interrupted
ART for at least 12 consecutive months and plasma samples from 30 subjects in the ART group who
continued receiving ART for 12 months. The plasma samples were collected from these 60 subjects at
baseline and 2, 4, 6, and 12 months after randomization. Additional selection criteria for our study
required subjects to have at least 5 years of total ART use prior to randomization and excluded subjects
who had viral loads exceeding 500 copies/ml in the year prior to randomization.
ELISA to assess gp120-speciﬁc IgG concentration and dimeric FcRIIIa binding. ELISAs to
determine the concentration of antibodies against HIV-1BaL gp120 (obtained from the NIH AIDS reagent
program [NIH-ARP]) within HIV-1 plasma were performed as previously described (43), with the
following modiﬁcation. Serial dilutions of the anti-gp120 monoclonal antibody 2G12 were included to
construct a standard curve, from which the concentration of gp120-speciﬁc antibodies within HIV-1
plasma was determined using nonlinear regression analysis.
The level of gp120-speciﬁc antibodies that can cross-link dimeric FcRIIIa was assessed as previously
described for inﬂuenza virus-speciﬁc ADCC antibodies (Fig. 1B) (44). Brieﬂy, ELISA plates were coated with
50 ng/well of HIV-1BaL gp120 and blocked with phosphate-buffered saline (PBS) containing 1% bovine
serum albumin (BSA). HIV-1 plasma samples were then added at a 1:100 dilution (panobinostat trial) or
a 1:1,000 dilution (SMART trial). Biotinylated recombinant dimeric FcRIIIa was added, followed by
horseradish peroxidase (HRP)-conjugated streptavidin (Thermo Fisher Scientiﬁc). The wells were devel-
oped with TMB substrate (Sigma-Aldrich) and the reaction was stopped with hydrochloric acid. The
absorbance values (450 nm) of the HIV-1 plasma samples were PBS background subtracted and
normalized to HIVIG (immune globulin prepared from plasma of HIV-1-infected donors) (NIH-ARP).
Infected-cell elimination ADCC assay. A modiﬁed version of the infected-cell elimination assay (45,
46) was performed to assess ADCC mediated by HIV-1 plasma obtained from the panobinostat and
SMART trials. Cells from the HIVLAV-infected 8E5/LAV cell line (NIH-ARP) was used as targets, with
approximately 50% of these cells expressing intracellular HIV-1 p24 (47). Healthy donor peripheral blood
mononuclear cells (PBMCs) were used as effector cells. Target 8E5/LAV cells were ﬁrst stained with the
viability dye LIVE/DEAD near-IR (Life Technologies) and the cell proliferation dye eFluor 670 (eBioscience),
whereas effector cells were stained with the cell proliferation dye eFluor 450 (eBioscience). The effector
and target cells were added to a 96-well V-bottom cell culture plate (Corning) at a 1:1 ratio in the
presence of HIV-1 plasma, HIV-1 plasma, or no plasma. The plasma samples were ﬁrst heat inactivated
at 56°C for 1 h and added at 10-fold dilutions from 1:100 to 1:100,000. The plate was centrifuged at 300
g for 1 min before a 5-h incubation at 37°C with 5% CO2. Cells were then ﬁxed with 1% formaldehyde
and permeabilized with 1 ﬂuorescence-activated cell sorting (FACS) permeabilization buffer (BD). An
antibody against HIV-1 p24 (clone KC57-RD1; Beckman Coulter) was then added to stain for HIV-1-
infected target cells. Lastly, cells were ﬁxed with 1% formaldehyde and acquired on an LSRFortessa
ﬂow cytometer (BD). Percent ADCC was calculated using the following formula: percent p24 cells
in {([targets  effectors]  [targets  effectors  plasma])  targets only}  100. Percent ADCC values
were plotted against log10(dilution1) for each time point of a subject, and the area under curve (AUC)
was calculated using GraphPad Prism 7. The resulting AUC values incorporate the percent ADCC values
for all four dilutions of each sample. The ADCC data shown in Results were averaged from 2 or 3
independent experiments.
Modeling of the ATI-induced stimulation of ADCC antibodies. To model the level of viremia
required for an increase in ADCC antibodies, we ﬁrst calculated the rate of change in ADCC antibodies
(r) using the formula
r
Iny2 Iny1
t2 t1
where y1 and y2 are the dimeric FcRIIIa-binding antibody levels (ADCC antibodies) at the ﬁrst and
second time points, respectively, with t1 and t2 being the ﬁrst and second time points. Next, the viral load
or difference in log10 viral load was plotted against the rate of ADCC. Orthogonal regression was then
performed in R (version 3.1.2) using the onls function from the onls library (version 0.1-1) to take into
account the measurement error in both the x axis (viral load) and y axis (rate of change in ADCC). The
threshold value to determine the level of viral load (VLthreshold) required for an increase in ADCC
antibodies was deﬁned as
VLthreshold 10
intercept
slope .
Statistics. Statistical analyses were performed with GraphPad Prism version 7. Comparisons between
matched groups were analyzed using the nonparametric Wilcoxon signed-rank test, and comparisons
between unmatched groups were analyzed using the nonparametric Mann-Whitney test. Comparisons
between multiple matched groups were analyzed using the nonparametric Friedman test followed with
Dunn’s multiple comparison posttest. Correlations were performed using the nonparametric Spearman
correlation test. P values of less than 0.05 were considered signiﬁcant. Statistics given in Results are
presented in the following format: (median [interquartile range] versus median [interquartile range]; P
value of statistical test).
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